Cargando…

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

PURPOSE: New direct-acting antiviral (DAA) drugs have revolutionized the treatment of hepatitis C in recent years. OBJECTIVE: Our objective was to analyse the cost effectiveness of combinations of different DAAs compared with ribavirin and peginterferon-α-2a, taking into account rebates from tender...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wisløff, Torbjørn, White, Richard, Dalgard, Olav, Amundsen, Ellen J., Meijerink, Hinta, Løvlie, Astrid Louise, Kløvstad, Hilde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906515/ https://www.ncbi.nlm.nih.gov/pubmed/29396744 http://dx.doi.org/10.1007/s40273-017-0604-3

Ejemplares similares

Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030
por: Meijerink, Hinta, et al.
Publicado: (2017)

Systematic screening with information and home sampling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial
por: Kløvstad, Hilde, et al.
Publicado: (2013)

Epidemiology of acute and chronic hepatitis B virus infection in Norway, 1992-2009
por: Rimšelienė, Gražina, et al.
Publicado: (2011)

Clinical and economic impact of universal varicella vaccination in Norway: A modeling study
por: Pawaskar, Manjiri, et al.
Publicado: (2021)

Minimal transmission of SARS-CoV-2 from paediatric COVID-19 cases in primary schools, Norway, August to November 2020
por: Brandal, Lin T, et al.
Publicado: (2021)

Population based study of genital Chlamydia trachomatis prevalence and associated factors in Norway: A cross sectional study
por: Kløvstad, Hilde, et al.
Publicado: (2012)

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
por: Seppälä, Elina, et al.
Publicado: (2021)

Comprehensive Contact Tracing, Testing and Sequencing Show Limited Transmission of SARS-CoV-2 between Children in Schools in Norway, August 2020 to May 2021
por: Winje, Brita Askeland, et al.
Publicado: (2021)

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2023)

Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway
por: Whelan, Jane, et al.
Publicado: (2016)

Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022
por: Langlete, Petter, et al.
Publicado: (2023)

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
por: Gountas, Ilias, et al.
Publicado: (2019)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

The correlation between socioeconomic factors and COVID-19 among immigrants in Norway: a register-based study
por: Kjøllesdal, Marte, et al.
Publicado: (2021)

Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China
por: Xie, Qing, et al.
Publicado: (2019)

High vaccine effectiveness against coronavirus disease 2019 (COVID-19) and severe disease among residents and staff of long-term care facilities in Norway, November 2020–June 2021
por: Starrfelt, Jostein, et al.
Publicado: (2022)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Are relative educational inequalities in multiple health behaviors widening? A longitudinal study of middle-aged adults in Northern Norway
por: Ibarra-Sanchez, Ana Silvia, et al.
Publicado: (2023)

Monitoring progress towards the first UNAIDS 90-90-90 target in key populations living with HIV in Norway
por: Whittaker, Robert, et al.
Publicado: (2020)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

COVID-19 among immigrants in Norway, notified infections, related hospitalizations and associated mortality: A register-based study
por: Indseth, Thor, et al.
Publicado: (2021)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States
por: Park, Haesuk, et al.
Publicado: (2019)

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection
por: Lin, Ming V., et al.
Publicado: (2016)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

A comparison of two registry-based systems for the surveillance of persons hospitalised with COVID-19 in Norway, February 2020 to May 2022
por: Whittaker, Robert, et al.
Publicado: (2023)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3dfi23etaks0t66h3he82o0k7r